Penn Davis McFarland’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.82M Sell
168,955
-460
-0.3% -$12.2K 0.41% 38
2026
Q2
$4.08M Sell
169,415
-946
-0.6% -$24.7K 0.36% 38
2026
Q1
$4.78M Sell
170,361
-971
-0.6% -$25.9K 0.47% 37
2025
Q4
$4.27M Buy
171,332
+57,777
+51% +$1.46M 0.41% 37
2025
Q3
$2.89M Sell
113,555
-6,810
-6% -$168K 0.3% 41
2025
Q2
$2.92M Buy
120,365
+20,295
+20% +$473K 0.33% 40
2025
Q1
$2.54M Sell
100,070
-390
-0.4% -$10.2K 0.3% 43
2024
Q4
$2.67M Sell
100,460
-1,370
-1% -$37.2K 0.29% 46
2024
Q3
$2.95M Buy
+101,830
New +$2.97M 0.33% 41
2021
Q2
– Sell
-6,107
Closed -$221K – 51
2021
Q1
$221K Sell
6,107
-6,000
-50% -$213K 0.04% 46
2020
Q4
$446K Sell
12,107
-289
-2% -$10.6K 0.1% 35
2020
Q3
$432K Buy
+12,396
New +$435K 0.11% 33
2020
Q1
– Sell
-6,072
Closed -$226K – 49
2019
Q4
$226K Buy
6,072
+200
+3% +$7.12K 0.07% 42
2019
Q3
$200K Buy
+5,872
New +$214K 0.06% 39

Other funds holding PFE

Penn Davis McFarland's PFE Position: Q3 2026 in Review

Penn Davis McFarland reduced its Pfizer (PFE) stake by 0.27% in Q3 2026, selling an estimated $12.2K and leaving 168,955 shares worth $4.82M. The position accounts for 0.41% of the portfolio, ranked #38.

Penn Davis McFarland first reported a position in PFE in Q3 2019 and has held it in 14 quarters since. 1,285 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • Penn Davis McFarland held 168,955 shares of Pfizer worth $4.82M as of Q3 2026.
  • Penn Davis McFarland sold 460 Pfizer shares in Q3 2026, an estimated $12.2K.
  • Pfizer made up 0.41% of Penn Davis McFarland's portfolio in Q3 2026, its #38 holding.
  • Penn Davis McFarland first reported a position in Pfizer in Q3 2019 and has held it in 14 quarters since.
  • 1,285 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on Penn Davis McFarland's 13F filing for Q3 2026, filed 23 Oct 2026.